Conatus Pharmaceuticals Inc (CNAT.OQ)

CNAT.OQ on NASDAQ Stock Exchange Global Market

10:23pm IST
Change (% chg)

$0.31 (+6.58%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Chart for


Conatus Pharmaceuticals Inc. is a biotechnology company. The Company focuses on the development and commercialization of medicines to treat liver disease. The Company operates through commercialization and development of pharmaceutical products segment. The Company is engaged in developing emricasan, which is an orally active... (more)


Beta: 1.29
Market Cap(Mil.): $174.93
Shares Outstanding(Mil.): 30.00
Dividend: --
Yield (%): --


BRIEF-Conatus Pharmaceuticals reports Q3 revenue of $9.6 million

* Conatus Pharmaceuticals Inc reports third quarter 2017 financial results and program updates

02 Nov 2017

BRIEF-EMA grants Conatus orphan drug designation for IDN-7314 for the treatment of PSC

* EMA grants Conatus orphan drug designation for IDN-7314 for the treatment of PSC

19 Oct 2017

BRIEF-Conatus Pharmaceuticals files for mixed shelf of upto $100 mln

* Conatus Pharmaceuticals Inc files for mixed shelf of upto $100 million - SEC filing Source text: (http://bit.ly/2x8wope) Further company coverage:

18 Aug 2017

BRIEF-Conatus announces completion of enrollment

* Conatus announces completion of enrollment in encore-NF phase 2B clinical trial of emricasan in patients with NASH fibrosis Source text for Eikon: Further company coverage:

15 Aug 2017


  Price Chg
BASF SE (BASFn.DE) €96.77 -0.90
Johnson & Johnson (JNJ.N) $147.59 +0.23
Novartis AG (NOVN.S) CHF83.46 +0.08
Merck & Co., Inc. (MRK.N) $61.23 -0.05
Roche Holding Ltd. (ROG.S) CHF235.80 +1.30
Roche Holding Ltd. (RO.S) CHF238.40 +0.60

Earnings vs. Estimates